Evidence supporting the use of: Lactobacillus rhamnosus
For the health condition: Colic (children)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Lactobacillus rhamnosus, particularly the strain L. rhamnosus GG (LGG), has been investigated for its potential to reduce symptoms of colic in infants. Colic is characterized by excessive crying in otherwise healthy infants, and while its precise etiology is not fully understood, alterations in the gut microbiota have been proposed as a contributing factor. Several randomized controlled trials and systematic reviews have assessed the efficacy of probiotics, including L. rhamnosus, in managing infantile colic.

A 2014 meta-analysis in Pediatrics found that some probiotic strains, particularly Lactobacillus reuteri, can reduce crying time in breastfed infants with colic, but the evidence for L. rhamnosus is less robust. A handful of studies have suggested that LGG may help modify gut microbiota and reduce inflammation, theoretically benefiting colicky infants. However, results are mixed and improvements are generally modest. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) currently does not recommend probiotics as a standard treatment for colic, citing insufficient evidence.

In summary, there is some scientific support for the use of L. rhamnosus in infantile colic, mostly related to its general effects on gut health and immune modulation, but the evidence is not strong or consistent. Thus, the use of L. rhamnosus for colic receives a moderate evidence rating (3/5), and parents should consult healthcare professionals before starting probiotic supplementation.

More about Lactobacillus rhamnosus
More about Colic (children)